Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics Inc. has been granted support by the Canadian Nuclear Laboratories through the CNRI-H Program to expedite the development of its innovative radio-immuno-conjugates, aimed at enhancing cancer treatments. This collaboration will focus on synthesizing and testing AccuTOX®-Trastuzumab constructs, which promise to improve the targeting and destruction of HER2-positive cancer cells, potentially overcoming resistance to current therapies.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
